AnaptysBio (ANAB) has drawn attention after recent share price moves, highlighted by its past year total return of 226.96%. Investors are assessing how this performance lines up with the company’s clinical pipeline and financial profile.

AnaptysBio’s recent share price has moved from short term swings to a steadier climb, with a 1 month share price return of 9.94% and a year to date share price return of 27.45%. The 1 year total shareholder return of 326.96% signals strong momentum building around the story at a current share price of US$57.29.

Scan beyond AnaptysBio and size up other high momentum biotech and pharma stocks with strong underlying fundamentals through our hand picked 20 high quality undiscovered gems list.

The surge in AnaptysBio now leaves a key issue on the table. Does this rerating mainly reflect progress in its immunology pipeline and financial profile, or has sentiment simply run ahead of what the business currently supports?

Most Popular Narrative: 36.3% Undervalued

According to the most followed narrative on AnaptysBio, a fair value of $90 sits well above the recent $57.29 share price. This puts the focus on how sustainable its royalty and litigation driven thesis really is.

ANAB has a scaling and rising royalty stream, one up and coming new royalty, a loan that dies in 2027 which will result in a doubling of revenue, and a lawsuit that could soon double the value of the stock.

Curious what assumptions support that $90 fair value for AnaptysBio? The narrative leans heavily on royalty expansion, margin rich cash flows and a sharp swing in profitability. The exact revenue ramp and profit profile behind that view might surprise you.

Result: Fair Value of $90 (UNDERVALUED)

However, this AnaptysBio royalty and litigation story still carries key risks, including an uncertain court outcome and any setback in partner product development or commercialization.

Next Steps

If the optimism in this AnaptysBio story feels compelling, consider acting while sentiment is fresh and test the numbers yourself. Start by reviewing the 2 key rewards

Looking for more investment ideas beyond AnaptysBio?

Do not stop with AnaptysBio. Use the Simply Wall Street Screener to line up other clear ideas so you are not relying on a single story.

• Target resilient balance sheets and steady fundamentals by reviewing the list of solid balance sheet and fundamentals (50 results) that could handle tougher conditions without forcing rushed decisions.
• Focus on quality at a reasonable price by scanning the 46 high quality undervalued stocks that match strong fundamentals with valuations that may leave room for upside.
• Prioritise stability and income potential by checking the 12 dividend fortresses that pair higher yields with businesses built to support regular payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.